⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43239 | 0.87 | — | — | |
| SCHEMBL10369336 | 0.87 | — | — | |
| Water SCHEMBL5898983 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL10616125 | 0.82 | — | — | |
| SCHEMBL8098370 | 0.82 | — | — | |
| Phosphine SCHEMBL5610956 | 0.82 | — | — | |
| SCHEMBL27839705 | 0.82 | — | — | |
| SCHEMBL10716587 | 0.72 | — | — | |
| SCHEMBL12995984 | 0.70 | — | — | |
| SCHEMBL15132741 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1789553-B1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS INC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8013136-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7723512-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090318676-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090281299-A1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| US-7615618-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20060287260-A1 | Ribonucleoside substituted with a phosphonamidite group at the 3'-position; the phosphonamidite may be an alkyl phosphonamidite; can be used to prepare oligonucleotides used in gene therapy; improved serum solubility, cellular distribution and uptake, and stability in vivo | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| EP-0900805-A2 | Incorporation of selectably cleavable and/or abasic sites into oligonucleotide chains and reagents therefor | CHIRON CORPORATION (US) | 1999-03-10 | — | — | EP | disclosed |
| US-5578717-A | Nucleotides for introducing selectably cleavable and/or abasic sites into oligonucleotides | CHIRON CORPORATION (US) | 1996-11-26 | — | — | US | disclosed |
| US-5552538-A | Oligonucleotides with cleavable sites | CHIRON CORPORATION (US) | 1996-09-03 | — | — | US | disclosed |
| US-5545730-A | Multifunctional nucleic acid monomer | CHIRON CORPORATION (US) | 1996-08-13 | — | — | US | disclosed |
| US-5430136-A | Oligonucleotides having selectably cleavable and/or abasic sites | CHIRON CORPORATION (US) | 1995-07-04 | — | — | US | disclosed |
| US-5367066-A | Oligonucleotides with selectably cleavable and/or abasic sites | CHIRON CORPORATION (US) | 1994-11-22 | — | — | US | disclosed |
| EP-0543889-A4 | INCORPORATION OF SELECTABLY CLEVABLE AND/OR ABASIC SITES INTO OLIGONUCLEOTIDE CHAINS AND REAGENTS THEREFOR | CHIRON CORP (US) | 1994-05-18 | — | — | EP | disclosed |
| EP-0543889-A1 | INCORPORATION OF SELECTABLY CLEVABLE AND/OR ABASIC SITES INTO OLIGONUCLEOTIDE CHAINS AND REAGENTS THEREFOR | CHIRON CORPORATION (US) | 1993-06-02 | — | — | EP | disclosed |
| WO-1992002528-A1 | INCORPORATION OF SELECTABLY CLEVABLE AND/OR ABASIC SITES INTO OLIGONUCLEOTIDE CHAINS AND REAGENTS THEREFOR | CHIRON CORPORATION (US) | 1992-02-20 | — | — | WO | disclosed |